Project Grant R01AG098771
- Federal Project Grant Award Summary Oregon Health & Science University received a $659,094 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) for a research initiative focused on early detection of Alzheimer's disease using noninvasive retinal fluorescence imaging. The project, which commenced on January 1, 2026, and extends through December 31, 2030, aims to develop novel imaging technology that leverages retinal assessment as a...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $10.1 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective June 1, 2025, through March 31, 2030, to establish the Vanderbilt Alzheimer's Disease Research Center (VADRC). The Center will deliver comprehensive research infrastructure and services focused on understanding the intersection between vascular risk factors and Alzheimer's disease and...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $1.47 million Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded January 1, 2026, with completion targeted for December 31, 2030. The grant supports research investigating mechanistic links between endothelial cell aging and dementia, with primary deliverables centered on developing a novel human induced pluripotent stem cell (iPSC)-derived endothelial cell model of...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $242,489 project grant award on September 2, 2025, from the National Institute on Aging under the Aging Research program (CFDA 93.866) to conduct proteomic research examining the pathophysiological mechanisms linking gait decline and cognitive impairment in older adults. The research project, titled "The Proteomic Signature of Dual Decline in Gait and Cognition," will leverage the Vanderbilt Memory...
- Federal Project Grant Award Summary Award Details: Vasoptic Medical, Inc. received a $500,000 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) awarded on September 20, 2025, with a completion date of September 19, 2026. The awardee is located in Columbia, Maryland. Products and Services: Under this Phase I project, Vasoptic Medical will develop VasoVue NV, an advanced imaging platform designed to enable rapid, noninvasive assessment of...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $3.53 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) to conduct a four-year research initiative investigating sex-specific genetic drivers of cerebrovascular disease in Alzheimer's disease brains. The award, effective September 1, 2025 through August 31, 2029, will support genome-wide analyses leveraging autopsy data from over 9,600 well-characterized...
- This $481,250 Project Grant was awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to Vanderbilt University Medical Center (VUMC) on September 1, 2024. The award supports the development of an innovative, non-invasive MRI imaging technique to assess membrane lipid properties in Alzheimer's disease (AD). The key objectives are to: 1) verify the relationship between the MRI nuclear Overhauser enhancement (NOE) signal and lipid properties using reconstituted phospholipid...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $3.15 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with a completion date of June 30, 2030. This research initiative investigates the relationship between serum psychotropic drug levels, drug metabolizer status (based on cytochrome P450 genotypes), and delirium duration in older hospitalized patients. The project...
- This federal Project Grant award, in the amount of $429,000.00, was provided by the National Institute on Aging (NIA) under the Aging Research grant program (CFDA 93.866). The grant supports research to characterize the biochemical and biological properties of amyloid-beta (Aβ) aggregates found in the eyes of Alzheimer's disease (AD) patients, and to evaluate the potential for these eye-derived Aβ aggregates to induce Aβ pathology in mouse models of AD. The research aims to understand if...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $149,889 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 1, 2025, with a completion date of May 31, 2030. This award supports a discovery-focused research initiative investigating the mechanistic association between epigenetic bone age measures, frailty indicators, and bone imaging findings using artificial intelligence (AI) and...
Vanderbilt University Medical Center received a $659,026 Project Grant award from the National Institute on Aging (CFDA 93.866, Aging Research program) effective March 1, 2026, with a completion date of February 28, 2031. The grant supports research to develop and validate a novel diagnostic imaging approach for early detection of Alzheimer's disease (AD) by detecting soluble amyloid-beta (Aβ) oligomers (SABOs) in the retina. The research team will utilize a proprietary fluorescein-labeled, SABO-specific nanobody to visualize SABO clearance dynamics in retinal blood vessels, taking advantage of the retina's accessibility and dense vascular network. This work addresses a critical clinical need, as SABOs appear years before amyloid plaques form and are believed to be primary drivers of neurodegeneration, yet no current disease-modifying therapies or early diagnostic methods exist for AD. The project deliverables include scientific advancement toward establishing retinal screening as a routine component of eye examinations for early AD detection. By visualizing SABO clearance processes in the retina using the innovative fluorescein-labeled nanobody, the research aims to enable identification of disease onset during the asymptomatic stage when therapeutic intervention is most effective. The award is positioned within the National Institute on Aging's broader mission to support biomedical research advancing understanding of aging processes and age-related diseases, with particular emphasis on preventing and treating Alzheimer's disease and related dementias.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $659.0k | 2/27/26 |